Insider Transactions in Q1 2024 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2024
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,079
+12.09%
|
-
|
|
Mar 14
2024
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,941
+20.96%
|
-
|
|
Mar 14
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
21,333
+13.02%
|
-
|
|
Mar 14
2024
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
61,490
+11.76%
|
-
|
|
Mar 06
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
8,109
-6.27%
|
$535,194
$66.88 P/Share
|
|
Mar 06
2024
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
857
-3.24%
|
$56,562
$66.88 P/Share
|
|
Mar 06
2024
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,725
-4.02%
|
$1,103,850
$66.88 P/Share
|
|
Mar 06
2024
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,103
-9.8%
|
$336,798
$66.88 P/Share
|
|
Mar 05
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
32,604
-9.93%
|
$2,184,468
$67.54 P/Share
|
|
Mar 05
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
28,604
+14.58%
|
$171,624
$6.67 P/Share
|
|
Mar 04
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
9,630
-6.74%
|
$645,210
$67.68 P/Share
|
|
Mar 04
2024
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,783
-6.32%
|
$119,461
$67.68 P/Share
|
|
Mar 04
2024
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
25,341
-5.74%
|
$1,697,847
$67.68 P/Share
|
|
Mar 04
2024
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,202
-4.06%
|
$147,534
$67.68 P/Share
|
|
Feb 14
2024
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
5,000
-10.5%
|
$380,000
$76.48 P/Share
|
|
Feb 14
2024
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.5%
|
$20,000
$4.44 P/Share
|
|
Feb 13
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$950,000
$76.85 P/Share
|
|
Feb 13
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Feb 06
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
32,605
-9.51%
|
$2,575,795
$79.29 P/Share
|
|
Feb 06
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
28,605
+14.01%
|
$171,630
$6.67 P/Share
|
|
Jan 31
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$987,500
$79.57 P/Share
|
|
Jan 31
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Jan 19
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$1,012,500
$81.42 P/Share
|
|
Jan 19
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Jan 12
2024
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
5,000
-10.5%
|
$425,000
$85.14 P/Share
|
|
Jan 12
2024
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.5%
|
$20,000
$4.44 P/Share
|
|
Jan 04
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
15,678
-4.91%
|
$1,348,308
$86.99 P/Share
|
|
Jan 04
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
11,678
+6.7%
|
$81,746
$7.96 P/Share
|
|
Jan 02
2024
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
148
+0.78%
|
$12,432
$84.12 P/Share
|
|
Jan 02
2024
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
74
+0.39%
|
$6,216
$84.12 P/Share
|
|
Jan 02
2024
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
74
+0.43%
|
$6,216
$84.12 P/Share
|
|
Jan 02
2024
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
148
+1.27%
|
$12,432
$84.12 P/Share
|
|
Jan 02
2024
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
252
+0.59%
|
$21,168
$84.12 P/Share
|
|
Jan 02
2024
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
148
+0.76%
|
$12,432
$84.12 P/Share
|
|
Jan 02
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$1,062,500
$85.08 P/Share
|
|
Jan 02
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|